The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|November 22, 2022
Rheumatoid Arthritis Quiz: Annual Booster Shots
Author(s)Ingrid Torjesen
Thanksgiving marks the start of darker days and colder temperatures and acts as a reminder to get those annual booster shots for influenza and COVID-19. Test your knowledge on booster shots for patients with rheumatoid arthritis.
Advertisement
Is the following statement true or false?
Concomitant methotrexate reduces the efficacy of a booster shot of SARS-CoV-2 mRNA vaccines in elderly but not younger patients with rheumatoid arthritis.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement